What to know first
Under $200/mo all-in is a meaningful threshold for cash-pay GLP-1. Below it, most patients can sustain treatment as a recurring expense; above $300 it competes with rent in many household budgets. Three programs deliver this without insurance via compounded GLP-1 (which carries regulatory exposure that has tightened through 2025-2026). One program delivers it with insurance via PA on branded Wegovy or Zepbound.
What we considered
- All-in monthly cost ≤$200 at sustainable dose
- Predictability: price doesn't increase at higher doses
- Cash-pay or insurance pathway clearly disclosed
- Regulatory exposure of the supply chain transparent
Some visit links earn us a commission.
Scores out of 10, equal-weighted across five dimensions. How we score
Top pick: Mochi Health

Mochi at $178/mo all-in is the cleanest under-$200 cash-pay option: flat monthly, no dose-based price increases, no insurance required.
Read the full Mochi Health review →
Other strong picks

